Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet

Cytokinetics' Myqorzo sales rose 427.1% quarter-over-quarter to $25.3 million in Q2 despite competition from Bristol Myers Squibb's Camzyos. Full Phase 3 ACACIA-HCM results published in the NEJM showed strong efficacy for Myqorzo in symptomatic nonobstructive hypertrophic cardiomyopathy, an indication where Camzyos failed. The clinical and commercial progress is positive, although Cytokinetics shares remain under pressure.

Analysis

CYTK’s investable inflection is not the initial commercial ramp alone, but the potential expansion from a crowded obstructive-HCM market into a less-penetrated nonobstructive segment where therapeutic differentiation could alter physician sequencing. If regulators accept the Phase 3 package and labeling supports broad use, Myqorzo could move from a share-take story to a market-expansion story, improving the durability of peak-sales assumptions and supporting multiple expansion over the next 6-18 months.

The nearer-term risk is that rapid early uptake reflects launch inventory, free-drug programs, or a concentrated set of specialist accounts rather than repeatable patient starts. The next two quarterly reports should therefore be judged on net revenue per patient, refill/persistence trends, gross-to-net deductions, and payer access—not headline prescription growth. Evidence of broad reimbursement without onerous step edits would be more consequential than another quarter of high percentage growth off a small base.

BMY faces a strategic rather than material earnings risk: its diversified revenue base makes a direct short an inefficient expression of the thesis. The relevant second-order effect is competitive spending—rebates, contracting, and specialist-sales intensity could compress category economics even if CYTK gains share. Consensus may be underpricing the possibility that meaningful nonobstructive differentiation reduces Camzyos’ ability to defend its incumbent position, while overpricing the speed at which clinical evidence converts to label expansion and payer adoption.

Key Decisions for Investors

• Accumulate CYTK over the next 1-3 months on weakness, sized as a catalyst-driven healthcare position; add only if the next earnings release demonstrates continued sequential net-sales growth alongside stable gross-to-net and improving payer coverage. The upside case is a re-rating on credible nonobstructive-HCM optionality; falsify if persistence, net price, or guidance deteriorates.
• Do not use an outright BMY short to express the competitive thesis: HCM economics are unlikely to move consolidated BMY earnings enough to overcome pipeline, capital-allocation, and broader pharma-factor exposure. If a hedge is required, use a modest CYTK long versus XBI or IBB short to isolate company-specific execution risk.
• Establish an alert around regulatory-labeling milestones and conference-level durability/safety updates over the next 6-12 months. A narrow label, safety imbalance, or delayed filing/review would materially reduce the addressable-market expansion thesis and warrants cutting CYTK exposure.
• Before using CYTK calls, verify implied volatility versus the expected timing of earnings and regulatory catalysts; use defined-risk call spreads only if option pricing does not already capitalize the label-expansion scenario. Avoid paying for long-dated optionality until the commercial quality of revenue is independently validated.